Sertoli-Leydig Cell Tumor: Causes, Symptoms, Diagnosis, and Treatment

~Introduction

Sertoli-Leydig Cell Tumor (SLCT) is a rare type of ovarian tumor that belongs to a group of cancers known as sex cord-stromal tumors. These tumors originate from the cells that normally help in the development of reproductive tissues and hormone production. Unlike many ovarian cancers that arise from epithelial cells, Sertoli-Leydig cell tumors develop from the specialized stromal cells of the ovary.

Although uncommon, Sertoli-Leydig cell tumors are clinically significant because they often produce androgens (male hormones). As a result, affected individuals may develop symptoms related to hormonal imbalance such as virilization, menstrual irregularities, and infertility.

SLCTs represent less than 0.5% of all ovarian tumors, making them one of the rarest ovarian neoplasms. Despite their rarity, most cases are diagnosed at an early stage, and the prognosis is generally favorable when treated appropriately.

This article provides a comprehensive overview of Sertoli-Leydig cell tumors, including their causes, symptoms, diagnosis, treatment options, and prognosis.

~What is a Sertoli-Leydig Cell Tumor?

A Sertoli-Leydig Cell Tumor is a rare ovarian tumor composed of Sertoli cells and Leydig cells, which are typically found in the testes in males. In females, similar cells exist within the ovarian stroma and can occasionally form tumors.

These tumors may produce hormones, particularly testosterone, which leads to masculinizing effects in affected individuals. The degree of hormone production and tumor differentiation determines the severity of symptoms.

SLCTs can be classified into three main categories based on their histological differentiation:

1. Well-differentiated tumors

2. Moderately differentiated tumors

3. Poorly differentiated tumors

The differentiation level is important because it helps doctors determine the tumor's aggressiveness and treatment approach.

~Epidemiology and Prevalence

Sertoli-Leydig cell tumors are extremely rare. They account for:

• Approximately 0.2–0.5% of all ovarian tumors

• Around 1–2% of sex cord-stromal tumors

These tumors most commonly occur in young women and adolescents, with the average age of diagnosis between 20 and 30 years. However, they can occur at any age, including childhood and postmenopausal women.

Most Sertoli-Leydig tumors affect only one ovary, and bilateral involvement is very uncommon.

~Causes and Risk Factors

The exact cause of Sertoli-Leydig cell tumors remains unknown, but several genetic and biological factors have been associated with their development.

1. Genetic Mutations

Research has shown that mutations in the DICER1 gene are strongly linked to the development of SLCTs. The DICER1 gene plays a critical role in regulating cell growth and gene expression. When mutated, it can lead to abnormal cell proliferation and tumor formation.

People with DICER1 syndrome, a rare hereditary condition, may have an increased risk of developing Sertoli-Leydig cell tumors along with other rare tumors.

2. Hormonal Influences

Since these tumors originate from hormone-producing cells, hormonal imbalance may contribute to tumor development. However, the exact mechanism remains unclear.

3. Age

Young women and adolescents appear to be more susceptible, although the reason for this age-related risk is not fully understood.

~Symptoms of Sertoli-Leydig Cell Tumor

The symptoms of SLCT largely depend on whether the tumor produces hormones. About 70–80% of these tumors produce androgens, leading to virilization symptoms.

Hormonal Symptoms

Common androgen-related symptoms include:

• Deepening of the voice

• Excess facial and body hair (hirsutism)

• Acne and oily skin

• Enlarged clitoris (clitoromegaly)

• Male-pattern baldness

• Increased muscle mass

These symptoms may develop gradually or rapidly depending on hormone levels.

Menstrual Changes

Many women experience menstrual abnormalities such as:

• Irregular periods

• Absence of menstruation (amenorrhea)

• Reduced fertility

Abdominal Symptoms

Some patients may develop symptoms related to the growing tumor, including:

• Pelvic pain

• Abdominal swelling

• Feeling of fullness

• A palpable abdominal mass

Non-Hormonal Symptoms

In rare cases, tumors do not produce hormones. These patients may only experience pelvic discomfort or abdominal enlargement.

~Types and Classification

Sertoli-Leydig cell tumors are classified based on their microscopic appearance and level of differentiation.

Well-Differentiated Tumors

These tumors closely resemble normal Sertoli and Leydig cells. They tend to grow slowly and are usually benign.

Moderately Differentiated Tumors

These tumors show intermediate features between well and poorly differentiated tumors. They may carry a moderate risk of malignancy.

Poorly Differentiated Tumors

These tumors appear highly abnormal under a microscope and are more aggressive. They have a higher likelihood of spreading beyond the ovary.

Retiform Variant

The retiform type is a rare subtype that resembles structures found in the rete testis. It usually occurs in younger patients.

Tumors with Heterologous Elements

Some tumors contain tissues not normally present in the ovary, such as cartilage, muscle, or intestinal-type glands. These are called heterologous elements and may affect the tumor’s behavior.

~Diagnosis of Sertoli-Leydig Cell Tumor

Early diagnosis is essential for effective treatment. Doctors typically use a combination of clinical evaluation, imaging studies, laboratory tests, and biopsy.

Medical History and Physical Examination

Doctors evaluate symptoms such as:

• Rapid onset of virilization

• Menstrual irregularities

• Pelvic mass

A physical exam may reveal signs of androgen excess.

Imaging Tests

Several imaging techniques help detect ovarian tumors.

Ultrasound
Pelvic ultrasound is often the first test used. It can identify ovarian masses and determine their size and structure.

CT Scan or MRI
These imaging methods provide more detailed information about the tumor and whether it has spread to surrounding tissues.

Hormone Testing

Blood tests may reveal elevated levels of:

• Testosterone

• Androstenedione

• Dehydroepiandrosterone (DHEA)

High androgen levels support the diagnosis of a hormone-producing tumor.

Tumor Markers

In some cases, doctors may measure tumor markers such as:

• Alpha-fetoprotein (AFP)

• Inhibin

• CA-125

These markers can help differentiate SLCT from other ovarian tumors.

Biopsy and Histopathology

The definitive diagnosis is made through histopathological examination of the tumor tissue after surgical removal. A pathologist studies the cells under a microscope to confirm the presence of Sertoli and Leydig cells.

~Treatment Options

Treatment for Sertoli-Leydig cell tumors depends on several factors including:

• Patient age

• Tumor stage

• Tumor differentiation

• Desire for fertility preservation

Surgery

Surgery is the primary treatment for most Sertoli-Leydig cell tumors.

Common surgical procedures include:

Unilateral Salpingo-Oophorectomy
Removal of the affected ovary and fallopian tube while preserving the uterus and opposite ovary. This option is often used for young women who want to maintain fertility.

Total Hysterectomy with Bilateral Salpingo-Oophorectomy
Removal of the uterus, both ovaries, and fallopian tubes. This may be recommended for older patients or advanced tumors.

Chemotherapy

Chemotherapy may be recommended for:

• Poorly differentiated tumors

• Advanced-stage disease

• Recurrent tumors

Common chemotherapy regimens include combinations of drugs such as:

• Bleomycin

• Etoposide

• Cisplatin (BEP regimen)

Radiation Therapy

Radiation therapy is rarely used but may be considered in specific cases where tumors cannot be fully removed.

~Prognosis and Survival Rate

The prognosis for Sertoli-Leydig cell tumors is generally excellent, especially when detected early.

Important factors influencing prognosis include:

• Tumor stage

• Degree of differentiation

• Presence of metastasis

Survival Statistics

• Early-stage tumors have survival rates above 90%

• Well-differentiated tumors have the best outcomes

• Poorly differentiated tumors have a higher recurrence risk

Because most SLCTs are diagnosed at Stage I, many patients recover completely after surgery.

~Complications

Although outcomes are usually positive, complications can occur, including:

• Tumor recurrence

• Hormonal imbalance

• Infertility

• Metastasis in aggressive cases

Regular follow-up is essential to monitor for recurrence.

~Follow-Up and Monitoring

Patients who have been treated for Sertoli-Leydig cell tumors require long-term monitoring.

Follow-up care typically includes:

• Regular pelvic examinations

• Imaging tests such as ultrasound

• Hormone level monitoring

• Tumor marker testing

Most recurrences occur within the first five years after treatment, so close monitoring during this period is critical.

~Fertility Considerations

Because many patients are young women, fertility preservation is an important aspect of treatment planning.

When the tumor is limited to one ovary, fertility-sparing surgery allows patients to retain reproductive capability. Many women can successfully conceive after treatment.

However, chemotherapy or extensive surgery may affect fertility, so patients should discuss reproductive options with their healthcare provider before treatment.

~Prevention and Risk Reduction

Currently, there is no known way to prevent Sertoli-Leydig cell tumors because the exact causes remain unclear.

However, individuals with a family history of DICER1 mutations may benefit from genetic counseling and regular medical screening.

Early medical evaluation for symptoms such as rapid virilization or unexplained hormonal changes can help ensure prompt diagnosis.

~Conclusion

Sertoli-Leydig cell tumors are rare ovarian tumors that arise from hormone-producing stromal cells. Although uncommon, they are clinically significant due to their ability to produce androgens and cause masculinizing symptoms.

Most cases occur in young women and are diagnosed at an early stage, allowing for effective treatment and a favorable prognosis. Surgery remains the primary treatment, while chemotherapy may be used in more aggressive cases.

Advances in genetic research, particularly the discovery of DICER1 mutations, have improved our understanding of these tumors and may lead to better diagnostic and treatment strategies in the future.

Early recognition of symptoms, proper diagnosis, and timely treatment are key factors in ensuring successful outcomes for patients with Sertoli-Leydig cell tumors.